Wizkuff-L Syrup is a combination pharmaceutical formulation containing Ambroxol (30mg), Levosalbutamol (1mg), and Guaifenesin (50mg) per dose, indicated for the management of respiratory conditions characterized by productive cough and bronchospasm. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of viscous mucus from the respiratory tract, thereby improving airway patency. Levosalbutamol, a selective β2-adrenergic receptor agonist, provides bronchodilation by relaxing bronchial smooth muscles, which aids in relieving bronchospasm and improving airflow. Guaifenesin serves as an expectorant, promoting the hydration of respiratory tract secretions and enhancing mucus clearance. The synergistic action of these active ingredients makes Wizkuff-L Syrup effective in treating acute and chronic bronchitis, asthma exacerbations, and other obstructive airway diseases with excessive mucus production. The syrup formulation ensures ease of administration, particularly in pediatric and geriatric populations. Dosage and duration of therapy should be guided by clinical assessment and severity of symptoms. Caution is advised in patients with hypersensitivity to any components, cardiovascular disorders, or hyperthyroidism. Adverse effects may include gastrointestinal disturbances, tremors, or allergic reactions. Consultation with a healthcare professional is recommended prior to use to ensure safety and efficacy.